Sign in to view content

Masked Safety Data from ZETA-1, an Ongoing 24-Week Phase 2 Clinical Trial of APX3330, an Oral Therapeutic Being Developed for the Treatment of Diabetic Retinopathy

Michael J Allingham, MD, PhD

Video
Published 2022

Related

Baseline DR Severity and Time to DME Resolution in Patients Treated With Ranibizumab in the RIDE and RISE Clinical Trials
Katherine E Talcott, MD
Annual Meeting Talks
2021
Phase 2 Trial of Ciliary Neurotrophic Factor for Macular Telangiectasia
Updates from the Field
2017
Treat-and-Extend Versus Bimonthly Dosing With Aflibercept for the Treatment of Diabetic Macular Edema, 1-Year Outcomes (EVADE Study)
Dilsher S. Dhoot, MD
Annual Meeting Talks
2018

Category: Diabetic Retinopathy

See more